35 research outputs found

    The role of transcriptional activator GATA-1 at human Ī²-globin HS2

    Get PDF
    GATA-1 is an erythroid activator that binds Ī²-globin gene promoters and DNase I hypersensitive sites (HSs) of the Ī²-globin locus control region (LCR). We investigated the direct role of GATA-1 interaction at the LCR HS2 enhancer by mutating its binding sites within minichromosomes in erythroid cells. Loss of GATA-1 in HS2 did not compromise interaction of NF-E2, a second activator that binds to HS2, nor was DNase I hypersensitivity at HS2 or the promoter of a linked Īµ-globin gene altered. Reduction of NF-E2 using RNAi confirmed the overall importance of this activator in establishing LCR HSs. However, recruitment of the histone acetyltransferase CBP and RNA pol II to HS2 was diminished by GATA-1 loss. Transcription of Īµ-globin was severely compromised with loss of RNA pol II from the transcription start site and reduction of H3 acetylation and H3K4 di- and tri-methylation in coding sequences. In contrast, widespread detection of H3K4 mono-methylation was unaffected by loss of GATA-1 in HS2. These results support the idea that GATA-1 interaction in HS2 has a prominent and direct role in co-activator and pol II recruitment conferring active histone tail modifications and transcription activation to a target gene but that it does not, by itself, play a major role in establishing DNase I hypersensitivity

    Subdural to subgaleal shunts: alternative treatment in infants with nonaccidental traumatic brain injury?

    No full text

    10 years of experience: treatment of pediatric arteriovenous malformations by Gamma Knife radiosurgery

    No full text

    Long-term results of endovascular treatment of intracranial aneurysms

    No full text

    Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer

    No full text
    Tumor anemia is common in patients with malignant tumors and it was repeatedly demonstrated to be associated with impaired prognosis in patients with malignant tumors. We conducted a retrospective analysis based on 553 patients with histologically proven epithelial ovarian cancer. Blood hemoglobin levels were determined before surgery and patients with value
    corecore